Aadi Bioscience Inc (AADI)
1.78
-0.06
(-3.26%)
USD |
NASDAQ |
Apr 24, 16:00
1.785
0.00 (0.00%)
Pre-Market: 20:00
Aadi Bioscience Cash from Operations (TTM): -59.66M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -59.66M |
September 30, 2023 | -61.33M |
June 30, 2023 | -57.57M |
March 31, 2023 | -51.54M |
December 31, 2022 | -49.64M |
Date | Value |
---|---|
September 30, 2022 | -50.76M |
June 30, 2022 | -59.94M |
March 31, 2022 | -52.40M |
December 31, 2021 | -22.42M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-61.33M
Minimum
Sep 2023
-22.42M
Maximum
Dec 2021
-51.70M
Average
-52.40M
Median
Mar 2022
Cash from Operations (TTM) Benchmarks
Aquestive Therapeutics Inc | -6.38M |
89bio Inc | -129.19M |
NovaBay Pharmaceuticals Inc | -4.131M |
Palatin Technologies Inc | -26.54M |
iBio Inc | -18.89M |